2018
Higher Volume Facilities are Associated with the Delivery of Lower Dose Radiation Therapy in the Treatment of Cutaneous T-Cell Lymphoma
Miccio J, Wilson L, Kann B, Jairam V, Beckta J, Yeboa D. Higher Volume Facilities are Associated with the Delivery of Lower Dose Radiation Therapy in the Treatment of Cutaneous T-Cell Lymphoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e334-e335. DOI: 10.1016/j.ijrobp.2018.07.1027.Peer-Reviewed Original Research
2008
Successful therapy of cutaneous Tcell lymphoma
Heald P, Latkowski J, Wilson L, Mark L. Successful therapy of cutaneous Tcell lymphoma. Expert Review Of Dermatology 2008, 3: 99-110. DOI: 10.1586/17469872.3.1.99.Peer-Reviewed Original Research
2007
Surveillance, Epidemiology, and End Results (SEER) Database Analysis of Stage IE Primary CD30+ Cutaneous T-Cell Lymphoma (PCCTCL)
Yu J, Blitzblau R, Decker R, Housman D, Wilson L. Surveillance, Epidemiology, and End Results (SEER) Database Analysis of Stage IE Primary CD30+ Cutaneous T-Cell Lymphoma (PCCTCL). International Journal Of Radiation Oncology • Biology • Physics 2007, 69: s536-s537. DOI: 10.1016/j.ijrobp.2007.07.1777.Peer-Reviewed Original ResearchEnd Results database analysisCutaneous T-cell lymphomaT-cell lymphomaPrimary CD30Database analysisCD30LymphomaEpidemiology
1999
Total skin electron radiation for patients with erythrodermic cutaneous T‐cell lymphoma (mycosis fungoides and the Sézary syndrome)
Jones G, Rosenthal D, Wilson L. Total skin electron radiation for patients with erythrodermic cutaneous T‐cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 1999, 85: 1985-1995. PMID: 10223240, DOI: 10.1002/(sici)1097-0142(19990501)85:9<1985::aid-cncr16>3.0.co;2-o.Peer-Reviewed Original ResearchConceptsErythrodermic mycosis fungoidesBlood involvementMycosis fungoidesCutaneous remissionSpecific survivalStage IIIErythrodermic cutaneous T-cell lymphomaTotal skin electron beam radiationMedian cause-specific survivalCutaneous T-cell lymphomaMedian overall survivalStage IVB diseaseCause-specific survivalStage III diseaseMedian radiation doseMedian treatment timeT-cell lymphomaToxicity of radiationIVB diseaseAdjuvant therapyStage IVAVisceral involvementModality therapyOverall survivalLymph nodesEvaluation of T-cell receptor gene rearrangements in patients with recurrent patch/plaque (T2) CTCL (mycosis fungoides).
Thayu M, Tallini G, Glusac E, Kacinski B, Wilson L. Evaluation of T-cell receptor gene rearrangements in patients with recurrent patch/plaque (T2) CTCL (mycosis fungoides). The Yale Journal Of Biology And Medicine 1999, 72: 365-75. PMID: 11138932, PMCID: PMC2579043.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDisease-free intervalMycosis fungoidesPolymerase chain reactionSkin biopsiesMedian disease-free intervalCutaneous T-cell lymphomaT-cell receptor gene rearrangementsDominant TCR clonesT-cell receptor gamma gene rearrangementEvaluation of patientsTissue samplesIdentification of patientsT-cell lymphomaGene rearrangementsReceptor gene rearrangementsGamma gene rearrangementsRecurrent mycosis fungoidesElectron beam therapyDominant TCRMF patientsTCR analysisTCR clonesMalignant lymphocytesT lymphocytes
1998
Local Superficial Radiotherapy in the Management of Minimal Stage IA Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Wilson L, Kacinski B, Jones G. Local Superficial Radiotherapy in the Management of Minimal Stage IA Cutaneous T-Cell Lymphoma (Mycosis Fungoides). International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 109-115. PMID: 9422565, DOI: 10.1016/s0360-3016(97)00553-1.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaStage IA mycosis fungoidesT-cell lymphomaAdjuvant therapyLocal controlMycosis fungoidesSuperficial radiationSuperficial radiotherapyDistant skin sitesMedian fraction numberMedian surface doseComplete response rateExcellent local controlDry desquamationPrior therapyHematologic toxicityPrior radiationDistant failurePersistent diseaseMedian ageCutaneous malignanciesPathologic documentationSurface doseMild erythemaPatients
1997
Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)
Quirós P, Jones G, Kacinski B, Braverman I, Heald P, Edelson R, Wilson L. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). International Journal Of Radiation Oncology • Biology • Physics 1997, 38: 1027-1035. PMID: 9276369, DOI: 10.1016/s0360-3016(97)00127-2.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDisease-free survivalT2 patientsCrude relapse rateAdjuvant therapyOverall survivalElectron beam therapyRelapse rateEntire cohortMedian disease-free survivalCutaneous T-cell lymphomaBeam therapySalvage of recurrencesAdjuvant systemic therapyEarly-stage patientsManagement of patientsT-cell lymphomaTopical nitrogen mustardDays/weekCombination of therapiesGy/dayTreatments/weekPUVA patientsMedian followSalvage therapy
1996
Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 1996, 35: 69-73. PMID: 8682967, DOI: 10.1016/s0190-9622(96)90499-5.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaComplete responseT-cell lymphomaElectron beam therapySecond courseMedian disease-free intervalThird courseAdditional coursesBeam therapyDisease-free intervalTreatment of patientsAcceptable risk profileForm of therapyMedian doseMedian survivalMild erythemaPatientsInitial courseTherapyVariety of modalitiesRisk profileEntire groupLocalized radiationExtent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy
Quiros P, Kacinski B, Wilson L. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy. Cancer 1996, 77: 1912-1917. PMID: 8646693, DOI: 10.1002/(sici)1097-0142(19960501)77:9<1912::aid-cncr23>3.0.co;2-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBody Surface AreaChemotherapy, AdjuvantCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRadiotherapy DosageRadiotherapy, High-EnergyRemission InductionRetrospective StudiesSkinSkin NeoplasmsSurvival RateConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaComplete clinical responseOverall survivalSkin involvementT-cell lymphomaMedian DFSPrognostic indicatorTotal skin electron beam radiation therapyToxicity of therapyElectron beam radiation therapyBeam radiation therapyTotal skin surfaceElectron beam therapyFree survivalClinical responsePrognostic significanceTumor nodulesRadiation therapyPatientsPatient recordsTherapyDiseaseBeam therapyMonths2159 Total skin electron beam therapy(TSEBT) followed by adjuvant psoralen/ultraviolet A light (PUVA) in the management of patients with T1 and T2 cutaneous T-cell lymphoma (CTCL)
Quiros P, Kacinski B, Heald P, Edelson R, Braverman I, Wilson L. 2159 Total skin electron beam therapy(TSEBT) followed by adjuvant psoralen/ultraviolet A light (PUVA) in the management of patients with T1 and T2 cutaneous T-cell lymphoma (CTCL). International Journal Of Radiation Oncology • Biology • Physics 1996, 36: 355. DOI: 10.1016/s0360-3016(97)85733-1.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaTotal skin electron beamManagement of patientsT-cell lymphomaPatientsLymphoma
1995
Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation
Licata A, Wilson L, Braverman I, Feldman A, Kacinski B. Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation. JAMA Dermatology 1995, 131: 432-435. DOI: 10.1001/archderm.1995.01690160060009.Peer-Reviewed Original ResearchTotal skin electron beam therapyCutaneous T-cell lymphomaT-cell lymphomaSquamous cell carcinomaBasal cell carcinomaElectron beam therapyAdditional radiation therapyCell carcinomaCutaneous malignanciesOral psoralenAdditional therapyMalignant melanomaRadiation therapyBeam therapyTotal skin electron beam radiationFurther radiation therapyGroup of patientsNonmelanoma skin cancerAnecdotal case reportsPrevious large studiesTopical mechlorethamineHydrochloride therapyCase reportPatientsCarcinoma
1994
Additional courses of total skin electron beam therapy [TSEBT] in the retreatment of patients with cutaneous t-cell lymphoma [CTCL]
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy [TSEBT] in the retreatment of patients with cutaneous t-cell lymphoma [CTCL]. International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 269. DOI: 10.1016/0360-3016(94)90825-7.Peer-Reviewed Original Research